Anticancer nanomedicines have been proven effective in mitigating the side effects of
chemotherapeutic drugs. However, challenges remain in augmenting their therapeutic …

The effectiveness of anticancer drugs in treating a solid tumour is dependent on delivery of
the drug to virtually all cancer cells in the tumour. The distribution of drug in tumour tissue …

Current cancer nanomedicines can only mitigate adverse effects but fail to enhance
therapeutic efficacies of anticancer drugs. Rational design of next‐generation cancer …

Hypoxia development in tumor is closely associated with its increased aggressiveness and
strong resistance to therapy, leading to the poor prognosis in several cancer types …

Precise nanomedicine has been extensively explored for efficient cancer imaging and
targeted cancer therapy, as evidenced by a few breakthroughs in their preclinical and …

The impermeable barrier of solid tumors due to the complexity of their components limits the
treatment effect of nanomedicine and hinders its clinical translation. Several methods are …

Cancer chemotherapy resistance (MDR) is the innate and/or acquired ability of cancer cells
to evade the effects of chemotherapeutics and is one of the most pressing major dilemmas in …

Cancer nanotherapeutics are progressing at a steady rate; research and development in the
field has experienced an exponential growth since early 2000's. The path to the …

The interface of bio–nano science and cancer medicine is an area experiencing much
progress but also beset with controversy. Core concepts of the field eg, the enhanced …

The liposome, a closed phospholipid bilayered vesicular system, has received considerable
attention as a pharmaceutical carrier of great potential over the past 30 years. The ability of …